Description: Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Home Page: www.genmab.com
GMAB Technical Analysis
Kalvebod Brygge 43
Copenhagen,
1560
Denmark
Phone:
45 70 20 27 28
Officers
| Name | Title |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO |
| Mr. Anthony Pagano | Exec. VP & CFO |
| Mr. Anthony Mancini | Exec. VP & COO |
| Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer |
| Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Director of Protein Production & Chemist and Non-Independent Director |
| Dr. Rima Bawarshi Nassar Ph.D. | VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director |
| Mr. Peter Ros | Sr. Director of Fin. & Accounting |
| Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations |
| Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 35.3357 |
|---|---|
| Trailing PE: | 35.7417 |
| Price-to-Book MRQ: | 8.0051 |
| Price-to-Sales TTM: | 2.463 |
| IPO Date: | 2009-06-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 1560 |